Takeda Pharmaceutical Company Limited (LON:0A87)
London
· Delayed Price · Currency is GBP · Price in USD 13.93
-1.05 (-7.01%)
At close: Apr 7, 2025
LON:0A87 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 | 3,197,812 | Upgrade
|
| Revenue Growth (YoY) | 7.45% | 5.87% | 12.85% | 11.61% | -2.84% | Upgrade
|
| Cost of Revenue | 1,580,217 | 1,431,505 | 1,253,163 | 1,127,308 | 1,013,655 | Upgrade
|
| Gross Profit | 3,001,334 | 2,832,257 | 2,774,315 | 2,441,698 | 2,184,157 | Upgrade
|
| Selling, General & Admin | 1,104,766 | 1,053,819 | 997,234 | 886,327 | 875,514 | Upgrade
|
| Research & Development | 730,227 | 728,617 | 633,325 | 526,087 | 455,765 | Upgrade
|
| Other Operating Expenses | 180,521 | 35,059 | 38,987 | 10,433 | 23,602 | Upgrade
|
| Operating Expenses | 2,552,218 | 2,339,020 | 2,154,648 | 1,841,636 | 1,760,110 | Upgrade
|
| Operating Income | 449,116 | 493,237 | 619,667 | 600,062 | 424,047 | Upgrade
|
| Interest Expense | -108,200 | -115,392 | -116,973 | -122,432 | -130,806 | Upgrade
|
| Interest & Investment Income | 46,549 | 11,628 | 5,781 | 4,763 | 2,153 | Upgrade
|
| Earnings From Equity Investments | -3,986 | 6,473 | -8,630 | -15,367 | 76 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -13,612 | -9,729 | -3,903 | -15,575 | Upgrade
|
| Other Non Operating Income (Expenses) | -82,966 | -31,520 | 3,975 | -26,119 | 1,118 | Upgrade
|
| EBT Excluding Unusual Items | 300,513 | 350,814 | 494,091 | 437,004 | 281,013 | Upgrade
|
| Merger & Restructuring Charges | - | -81,358 | -59,234 | -83,836 | -115,875 | Upgrade
|
| Gain (Loss) on Sale of Investments | -18,900 | - | 22,416 | 8,482 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 7,975 | 8,901 | 8,164 | 235,117 | Upgrade
|
| Asset Writedown | -106,529 | -139,809 | -62,484 | -54,421 | -17,521 | Upgrade
|
| Legal Settlements | - | -45,212 | -16,455 | -20,319 | -17,401 | Upgrade
|
| Other Unusual Items | - | -39,619 | -12,145 | 7,497 | 902 | Upgrade
|
| Pretax Income | 175,084 | 52,791 | 375,090 | 302,571 | 366,235 | Upgrade
|
| Income Tax Expense | 66,941 | -91,406 | 58,052 | 72,405 | -9,936 | Upgrade
|
| Earnings From Continuing Operations | 108,143 | 144,197 | 317,038 | 230,166 | 376,171 | Upgrade
|
| Minority Interest in Earnings | -215 | -130 | -21 | -107 | -166 | Upgrade
|
| Net Income | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 | Upgrade
|
| Net Income to Common | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 | Upgrade
|
| Net Income Growth | -25.09% | -54.55% | 37.80% | -38.81% | 749.90% | Upgrade
|
| Shares Outstanding (Basic) | 1,579 | 1,564 | 1,552 | 1,564 | 1,562 | Upgrade
|
| Shares Outstanding (Diluted) | 1,605 | 1,580 | 1,570 | 1,577 | 1,574 | Upgrade
|
| Shares Change (YoY) | 1.58% | 0.67% | -0.46% | 0.23% | 0.47% | Upgrade
|
| EPS (Basic) | 68.35 | 92.09 | 204.29 | 147.14 | 240.72 | Upgrade
|
| EPS (Diluted) | 67.23 | 91.16 | 201.94 | 145.87 | 238.96 | Upgrade
|
| EPS Growth | -26.25% | -54.86% | 38.44% | -38.96% | 745.88% | Upgrade
|
| Free Cash Flow | 856,387 | 540,924 | 836,499 | 999,853 | 899,725 | Upgrade
|
| Free Cash Flow Per Share | 533.46 | 342.28 | 532.85 | 633.95 | 571.78 | Upgrade
|
| Dividend Per Share | 196.000 | 188.000 | 180.000 | 180.000 | 180.000 | Upgrade
|
| Dividend Growth | 4.25% | 4.44% | - | - | - | Upgrade
|
| Gross Margin | 65.51% | 66.43% | 68.88% | 68.41% | 68.30% | Upgrade
|
| Operating Margin | 9.80% | 11.57% | 15.39% | 16.81% | 13.26% | Upgrade
|
| Profit Margin | 2.36% | 3.38% | 7.87% | 6.45% | 11.76% | Upgrade
|
| Free Cash Flow Margin | 18.69% | 12.69% | 20.77% | 28.02% | 28.14% | Upgrade
|
| EBITDA | 1,210,512 | 1,137,698 | 1,210,650 | 1,183,213 | 983,718 | Upgrade
|
| EBITDA Margin | 26.42% | 26.68% | 30.06% | 33.15% | 30.76% | Upgrade
|
| D&A For EBITDA | 761,396 | 644,461 | 590,983 | 583,151 | 559,671 | Upgrade
|
| EBIT | 449,116 | 493,237 | 619,667 | 600,062 | 424,047 | Upgrade
|
| EBIT Margin | 9.80% | 11.57% | 15.39% | 16.81% | 13.26% | Upgrade
|
| Effective Tax Rate | 38.23% | - | 15.48% | 23.93% | - | Upgrade
|
Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.